AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23499604 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (IM) influenza vaccine (standard dose)
Number of subjects: 4292
Study 22110169 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (EPA, DHA, ALA)
Number of subjects: 1014
Study 22110169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1014
Study 19767793 — intervention group
Group type: EXPERIMENTAL
Intervention: High-CHO energy-restricted diet (low fat)
Number of subjects: 40
Study 19767793 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-CHO energy-restricted diet (high fat)
Number of subjects: 40
Study 19767793 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (measured with a triaxial accelerometer and questionnaire)
Number of subjects: 40
Study 17965792 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention (1200-1400 kcal/day diet with 25% proteins, 25% fat, 50% carbohydrates plus 25-30 gm of fiber per week)
Number of subjects: 46
Study 17965792 — intervention group
Group type: COMPARATOR
Intervention: Metformin (850 mg twice daily)
Number of subjects: 46
Study 15257499 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapler haemorrhoidectomy
Number of subjects: 80
Study 15257499 — intervention group
Group type: COMPARATOR
Intervention: Conventional haemorrhoidectomy (control group)
Number of subjects: 80
Study 12149103 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (mean dose 17 mg/day)
Number of subjects: 32
Study 12149103 — intervention group
Group type: COMPARATOR
Intervention: Losartan (mean dose 77 mg/day)
Number of subjects: 32
Study 9794859 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care plus additional training for doctors and nurses (1.5 days' group training)
Number of subjects: 250
Study 9794859 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 250
Study 8083697 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine 100 mg/m2 orally
Number of subjects: 17
Study 8083697 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine 30 mg/m2 intravenously (IV)
Number of subjects: 17
Study 2666482 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg of ACETM
Number of subjects: 3
Study 2666482 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitization to ASA followed by rechallenge with 1000 mg of ACETM
Number of subjects: 3
Study 2666482 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitization to increasing doses of ACETM
Number of subjects: 3
Study 589351 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 216
Study 589351 — intervention group
Group type: COMPARATOR
Intervention: Chlorpropamide
Number of subjects: 216
Study 589351 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Metformin and Chlorpropamide
Number of subjects: 216
Study 31526852 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous night's nonrestorative sleep
Number of subjects: 220
Study 31526852 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning pain catastrophizing
Number of subjects: 220
Study 31526852 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater nonrestorative sleep and higher morning pain catastrophizing
Number of subjects: 220
Study 31733362 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher priced placebo cream
Number of subjects: 19
Study 31733362 — intervention group
Group type: COMPARATOR
Intervention: Lower priced placebo cream
Number of subjects: 19
Study 30077564 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure telemonitoring with pharmacist case management
Number of subjects: 228
Study 26360148 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue (MB) 1 ml at a concentration of 0.5%
Number of subjects: 115
Study 26360148 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 115
Study 26360148 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (MB and control)
Number of subjects: 115
Study 25399274 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure with the device (n=463)
Number of subjects: 707
Study 25399274 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (n=244; target INR 2-3)
Number of subjects: 707
Study 25399274 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (n=244)
Number of subjects: 707
Study 22539536 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated rehabilitation protocol
Number of subjects: 70
Study 22539536 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation protocol
Number of subjects: 70
Study 22539536 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 20461008 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) with isoniazid, rifampicin, pyrazinamide, and ethambutol
Number of subjects: 60
Study 20461008 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid, rifampicin, pyrazinamide, and ethambutol
Number of subjects: 60
Study 17564692 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional DVD (10 min)
Number of subjects: 36
Study 17564692 — intervention group
Group type: COMPARATOR
Intervention: Traditional face-to-face teaching (20 min)
Number of subjects: 36
Study 17564692 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study 15764752 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-generation agents (e.g., gemcitabine, taxanes, vinorelbine)
Number of subjects: 230
Study 15764752 — intervention group
Group type: EXPERIMENTAL
Intervention: Best supportive care
Number of subjects: 230
Study 15764752 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line chemotherapy
Number of subjects: 230
Study 15764752 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line chemotherapy
Number of subjects: 230
Study 15764752 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum plus a third-generation drug
Number of subjects: 230
Study 11996639 — intervention group
Group type: EXPERIMENTAL
Intervention: Trizivir (zidovudine, lamivudine, abacavir), dosing schedule of one pill twice-daily
Number of subjects: 0
Study 11996639 — intervention group
Group type: COMPARATOR
Intervention: Protease inhibitor-based regimens (e.g., indinavir)
Number of subjects: 0
Study 11996639 — intervention group
Group type: EXPERIMENTAL
Intervention: Trizivir
Number of subjects: 0
Study 9918268 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical markers and BMD
Number of subjects: 74
Study 9918268 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain
Number of subjects: 74
Study 9918268 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone Mineral Density (BMD)
Number of subjects: 74
Study 9918268 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebral fractures
Number of subjects: 74
Study 9918268 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 74
Study 9918268 — intervention group
Group type: EXPERIMENTAL
Intervention: Height
Number of subjects: 74
Study 7493436 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (subcutaneous)
Number of subjects: 18
Study 7493436 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 18
Study 2034777 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured guidance intervention
Number of subjects: 20
Study 2034777 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 16435478 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for duodenal ulcer
Number of subjects: 88
Study 31093681 — intervention group
Group type: EXPERIMENTAL
Intervention: health advice + app
Number of subjects: 110
Study 31093681 — intervention group
Group type: COMPARATOR
Intervention: health advice
Number of subjects: 110
Study 28982352 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary closure (SC) group
Number of subjects: 0
Study 28982352 — intervention group
Group type: COMPARATOR
Intervention: Primary closure (PC) group
Number of subjects: 0
Study 28982352 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane based primary closure (MBPC) group
Number of subjects: 0
Study 28982352 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study 26426863 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination with scar
Number of subjects: 3801
Study 26426863 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination with positive TST response
Number of subjects: 3801
Study 26426863 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination with both scar and positive TST
Number of subjects: 3801
Study 26426863 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination with scar and positive TST
Number of subjects: 3801
Study 25015354 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg/d DHA
Number of subjects: 78
Study 25015354 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus daily multivitamin
Number of subjects: 78
Study 23031506 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive supranuclear palsy
Number of subjects: 59
Study 23031506 — intervention group
Group type: EXPERIMENTAL
Intervention: Parkinson's disease
Number of subjects: 59
Study 23031506 — intervention group
Group type: COMPARATOR
Intervention: Healthy older adults
Number of subjects: 59
Study 20085600 — intervention group
Group type: EXPERIMENTAL
Intervention: Birch pollen extract
Number of subjects: 62
Study 20085600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 17516397 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 7.5% cream administered topically every other day for 20 days
Number of subjects: 21
Study 17516397 — intervention group
Group type: COMPARATOR
Intervention: Intravenous meglumine antimoniate administered at a dosage of 20 mg/kg per day every day for 20 days
Number of subjects: 21
Study 17516397 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with intravenous meglumine antimoniate and imiquimod 7.5% cream
Number of subjects: 21
Study 15366587 — intervention group
Group type: EXPERIMENTAL
Intervention: Yigu capsule (YGC)
Number of subjects: 210
Study 15366587 — intervention group
Group type: COMPARATOR
Intervention: Osteocalcin capsule
Number of subjects: 210
Study 15366587 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 210
Study 11422018 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (40 mg)
Number of subjects: 12
Study 11422018 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (5 mg)
Number of subjects: 12
Study 11422018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9722128 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (10 mg/day)
Number of subjects: 120
Study 9722128 — intervention group
Group type: EXPERIMENTAL
Intervention: Propanolol (20 mg/day and 40 mg during the menstrual period)
Number of subjects: 120
Study 9722128 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (0.75 mg/day)
Number of subjects: 120
Study 9722128 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine (300 mg/day)
Number of subjects: 120
Study 9722128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 7740595 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal problem-solving skills training (IPSST)
Number of subjects: 39
Study 7740595 — intervention group
Group type: COMPARATOR
Intervention: Control treatment condition (brief problem-oriented approach)
Number of subjects: 39
Study 7740595 — intervention group
Group type: EXPERIMENTAL
Intervention: IPSST
Number of subjects: 39
Study 3259170 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine, 30 mg intramuscularly four times a day for 5 days
Number of subjects: 26
Study 3259170 — intervention group
Group type: COMPARATOR
Intervention: Placebo, two capsules orally four times a day for the last 2 study days
Number of subjects: 26
Study 3259170 — intervention group
Group type: COMPARATOR
Intervention: Aspirin, two 325 mg capsules orally four times a day for the same schedule
Number of subjects: 26
Study 29573863 — intervention group
Group type: EXPERIMENTAL
Intervention: Optive Fusion (OF) - carmellose 0.5% and hyaluronic acid 0.1%
Number of subjects: 19
Study 29573863 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 19
Study 29573863 — intervention group
Group type: EXPERIMENTAL
Intervention: Optive Fusion (OF)
Number of subjects: 19
Study 28460284 — intervention group
Group type: EXPERIMENTAL
Intervention: FAR intervention (training to recognize emotional information, conveyed by changes in facial features)
Number of subjects: 39
Study 28460284 — intervention group
Group type: COMPARATOR
Intervention: Attention-to-facial-features intervention (training to detect changes in facial features)
Number of subjects: 39
Study 28460284 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 39
Study 25416642 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 IU intranasal oxytocin (OT)
Number of subjects: 304
Study 25416642 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 IU intranasal vasopressin (AVP)
Number of subjects: 304
Study 25416642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study 22390550 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingival unit grafts (n = 8)
Number of subjects: 17
Study 22390550 — intervention group
Group type: COMPARATOR
Intervention: Palatal grafts (n = 9)
Number of subjects: 17
Study 16724185 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone at 30 mg/day
Number of subjects: 43
Study 16724185 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of oral micronized progesterone (60 mg/day and 200 mg/day)
Number of subjects: 43
Study 16724185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 12729080 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% w/v silver nitrate solution
Number of subjects: 4
Study 12729080 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% w/v silver nitrate solution
Number of subjects: 4
Study 12729080 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% w/v silver nitrate solution
Number of subjects: 4
Study 12729080 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% w/v silver nitrate solution
Number of subjects: 4
Study 12729080 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% w/v silver nitrate solution buffered to pH 6
Number of subjects: 4
Study 12729080 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% w/v silver nitrate solution at pH 3.4, 4.2, 4.4, and 4.9
Number of subjects: 4
Study 10426831 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose sibrafiban (dosage based on body weight and renal function, administered every 12 hours)
Number of subjects: 9000
Study 10426831 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sibrafiban (dosage based on body weight and renal function, administered every 12 hours)
Number of subjects: 9000
Study 10426831 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (80 mg every 12 hours)
Number of subjects: 9000
Study 10426831 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (including aspirin and both doses of sibrafiban)
Number of subjects: 9000
Study 8718440 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly comparisons with feedback
Number of subjects: 124
Study 8718440 — intervention group
Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 124
Study 1831504 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline fiber
Number of subjects: 113
Study 1831504 — intervention group
Group type: COMPARATOR
Intervention: Control fiber
Number of subjects: 113
Study 1831504 — intervention group
Group type: COMPARATOR
Intervention: Scaling with root planing
Number of subjects: 113
Study 1831504 — intervention group
Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 113
Study 6961944 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertransfusion (Hb: 16-18 g/dl)
Number of subjects: 19
Study 6961944 — intervention group
Group type: COMPARATOR
Intervention: Normotransfusion (Hb: 12-14 g/dl)
Number of subjects: 19
Study 31736460 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg rapamycin (RET + RAP)
Number of subjects: 75
Study 31736460 — intervention group
Group type: COMPARATOR
Intervention: Placebo (RET + PBO)
Number of subjects: 75
Study 31736460 — intervention group
Group type: COMPARATOR
Intervention: 10 mg rapamycin without subsequent retrieval (NO RET + RAP)
Number of subjects: 75
Study 31253485 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol ointment
Number of subjects: 33
Study 31253485 — intervention group
Group type: COMPARATOR
Intervention: Testosterone ointment
Number of subjects: 33
Study 31253485 — intervention group
Group type: COMPARATOR
Intervention: Neutral base ointment
Number of subjects: 33
Study 31253485 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 33
Study 29149038 — intervention group
Group type: EXPERIMENTAL
Intervention: Hunger training with booklet entry (at least 60 days of recommended 63 days)
Number of subjects: 50
Study 25734980 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal prasterone (6.5 mg daily for 12 weeks)
Number of subjects: 0
Study 23494214 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-TT
Number of subjects: 400
Study 23494214 — intervention group
Group type: COMPARATOR
Intervention: MenPS
Number of subjects: 400
Study 21695210 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7 (2+1 doses)
Number of subjects: 1005
Study 21695210 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7 (2 doses)
Number of subjects: 1005
Study 21695210 — intervention group
Group type: COMPARATOR
Intervention: No PCV7 (controls)
Number of subjects: 1005
Study 19929217 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg for 3 months
Number of subjects: 99
Study 19929217 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 99
Study 16709427 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized feedback letters generated by computerized expert‐system technology
Number of subjects: 485
Study 16709427 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 485
Study 15223851 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg)
Number of subjects: 35
Study 15223851 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil (10 mg)
Number of subjects: 35
Study 11419681 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 82
Study 11419681 — intervention group
Group type: COMPARATOR
Intervention: Artesunate
Number of subjects: 82
Study 9413772 — intervention group
Group type: EXPERIMENTAL
Intervention: Bier's block
Number of subjects: 142
Study 9413772 — intervention group
Group type: COMPARATOR
Intervention: Haematoma block
Number of subjects: 142
Study 9413772 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalinised haematoma block
Number of subjects: 142
Study 9413772 — intervention group
Group type: COMPARATOR
Intervention: Non-alkalinised haematoma block
Number of subjects: 142
Study 8496540 — intervention group
Group type: EXPERIMENTAL
Intervention: High osmolality contrast medium
Number of subjects: 505
Study 8496540 — intervention group
Group type: COMPARATOR
Intervention: Low osmolality contrast medium
Number of subjects: 505
Study 2957971 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminohydroxybutylidene diphosphonate (2.5 mg/d intravenously for five days)
Number of subjects: 28
Study 2957971 — intervention group
Group type: COMPARATOR
Intervention: Dichloromethylene diphosphonate (300 mg/d intravenously for seven days, followed by 100 mg/d intramuscularly for ten days)
Number of subjects: 28
Study 2957971 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminohydroxybutylidene diphosphonate
Number of subjects: 28
Study 2957971 — intervention group
Group type: COMPARATOR
Intervention: Dichloromethylene diphosphonate
Number of subjects: 28
Study 29391492 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal-emphasized robotic rehabilitation (D-IMT)
Number of subjects: 40
Study 29391492 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal-emphasized robotic rehabilitation (P-IMT)
Number of subjects: 40
Study 29391492 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (CT)
Number of subjects: 40
Study 26950307 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose (LD) adalimumab weekly
Number of subjects: 188
Study 26950307 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose (HD) adalimumab weekly
Number of subjects: 188
Study 26950307 — intervention group
Group type: COMPARATOR
Intervention: Every other week (EOW) adalimumab
Number of subjects: 188
Study 25213147 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus rhamnosus HN001)
Number of subjects: 48
Study 25213147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 23758800 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ghrelin (2 μg/kg, n = 10)
Number of subjects: 20
Study 20923392 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh Frozen Plasma (FFP)
Number of subjects: 60
Study 20923392 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% Human Albumin
Number of subjects: 60
Study 20923392 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 60
Study 20923392 — intervention group
Group type: EXPERIMENTAL
Intervention: FFP, Albumin, Saline (all groups)
Number of subjects: 60
Study 18158364 — intervention group
Group type: EXPERIMENTAL
Intervention: VOCs exposure
Number of subjects: 130
Study 18158364 — intervention group
Group type: EXPERIMENTAL
Intervention: VOCs+O3 exposure
Number of subjects: 130
Study 18158364 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient or filtered air with a 1‐minute spike of VOCs (masked clean air)
Number of subjects: 130
Study 18158364 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech stressor
Number of subjects: 130
Study 18158364 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple arithmetic
Number of subjects: 130
Study 16374881 — intervention group
Group type: EXPERIMENTAL
Intervention: EZ-STEP sequence
Number of subjects: 15
Study 16374881 — intervention group
Group type: COMPARATOR
Intervention: Conventional MRA
Number of subjects: 15
Study 12969204 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine citrate 3 mg/kg
Number of subjects: 127
Study 12969204 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine citrate 15 mg/kg
Number of subjects: 127